You are here

CAR-T

On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy

On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy

Xconomy

Seattle Children's

pediatric cancer

Flag link:

Cell therapy emergence opens up new markets for shippers, logistic companies

Cell therapy emergence opens up new markets for shippers, logistic companies

BioPharma Dive

Flag link:

New Novartis CEO Narasimhan will face plenty of obstacles despite CAR-T triumph

New Novartis CEO Narasimhan will face plenty of obstacles despite CAR-T triumph

Fierce Biotech

Flag link:

Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR-T

Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR-T

Xconomy

clinical trials

Flag link:

Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better

Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better

Motley Fool

Gilead Sciences

Flag link:

Novartis follows up on big CAR-T win by naming Vas Narasimhan as its new CEO

Novartis follows up on big CAR-T win by naming Vas Narasimhan as its new CEO

Endpoints

Flag link:

At $475,000, new cancer drug raises thorny questions about drug pricing — and value

At $475,000, new cancer drug raises thorny questions about drug pricing — and value

Stat

Flag link:

3 Biotech Stocks That Skyrocketed This Past Week

3 Biotech Stocks That Skyrocketed This Past Week

Motley Fool

Abeona Therapeutics

Sangamo BioSciences

Juno Therapeutics

Flag link:

Takeda partners with Noile-Immune on next-gen CAR-T pipeline for solid tumors

Takeda partners with Noile-Immune on next-gen CAR-T pipeline for solid tumors

Endpoints

Flag link:

Neurotoxicity kills a CAR-T rival pushed by J&J, MacroGenics in $700M deal

Neurotoxicity kills a CAR-T rival pushed by J&J, MacroGenics in $700M deal

Endpoints

Flag link:

Landmark approval won, Novartis' next test is scaling CAR-T manufacturing

Landmark approval won, Novartis' next test is scaling CAR-T manufacturing

BioPharma Dive

drug manufacturing

Flag link:

Profit on $475,000 Novartis cancer drug could be a while coming

Profit on $475,000 Novartis cancer drug could be a while coming

Yahoo/Reuters

Flag link:

Why bluebird bio Inc Continued Its March Higher Again Today

Why bluebird bio Inc Continued Its March Higher Again Today

Motley Fool

Gilead Sciences

Flag link:

Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences

Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences

Motley Fool

Gilead Sciences

Flag link:

A Cancer Doc Weighs In On CAR-T, Precision Medicine And Pricing Debates

A Cancer Doc Weighs In On CAR-T, Precision Medicine And Pricing Debates

Forbes

precision medicine

Flag link:

Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?

Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?

Forbes

acute lymphoblastic leukemia

Flag link:

Novartis Wins Historic FDA Nod, Prices CAR-T For Leukemia at $475,000

Novartis Wins Historic FDA Nod, Prices CAR-T For Leukemia at $475,000

Xconomy

acute lymphoblastic leukemia

Flag link:

Has Gilead Sciences' Big Bounce Begun With the Kite Pharma Buyout?

Has Gilead Sciences' Big Bounce Begun With the Kite Pharma Buyout?

Motley Fool

Gilead Sciences

Flag link:

How will Gilead price CAR-T? With Kite buy, the top biotech joins Novartis in spotlight

How will Gilead price CAR-T? With Kite buy, the top biotech joins Novartis in spotlight

Fierce Pharma

Gilead Sciences

Flag link:

Here's What Else Gilead Sciences Gets by Buying Kite Pharma

Here's What Else Gilead Sciences Gets by Buying Kite Pharma

Motley Fool

Gilead Sciences

TCR-targeted drugs

Flag link: